{"id":"https://openalex.org/W4405048838","doi":"https://doi.org/10.1182/blood-2024-198684","title":"Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma","display_name":"Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma","publication_year":2024,"publication_date":"2024-11-05","ids":{"openalex":"https://openalex.org/W4405048838","doi":"https://doi.org/10.1182/blood-2024-198684"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2024-198684","doi":"https://doi.org/10.1182/blood-2024-198684","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2024-198684","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067489954","display_name":"Veronika Bachanov\u00e1","orcid":"https://orcid.org/0000-0002-9325-432X","observed_orcids":["https://orcid.org/0000-0002-9325-432X"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Veronika Bachanova","raw_affiliation_strings":["1Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051092535","display_name":"Abhinav Deol","orcid":"https://orcid.org/0000-0003-0947-8871","observed_orcids":["https://orcid.org/0000-0003-0947-8871"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]},{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abhinav Deol","raw_affiliation_strings":["2Karmanos Cancer Institute/Wayne State University, Detroit, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Karmanos Cancer Institute/Wayne State University, Detroit, MI","institution_ids":["https://openalex.org/I185443292","https://openalex.org/I4210090317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043100252","display_name":"Taha Mahdi Salih Al-Juhaishi","orcid":"https://orcid.org/0000-0002-8359-0178","observed_orcids":["https://orcid.org/0000-0002-8359-0178","https://orcid.org/0009-0003-7220-2314"]},"institutions":[{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taha Mahdi Salih Al-Juhaishi","raw_affiliation_strings":["3Hematology and Medical Oncology, Stem Cell Transplantation and Cellular Therapy Program, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, OK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hematology and Medical Oncology, Stem Cell Transplantation and Cellular Therapy Program, University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, OK","institution_ids":["https://openalex.org/I4390039380","https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058005688","display_name":"Premal Lulla","orcid":"https://orcid.org/0000-0002-7707-2331","observed_orcids":["https://orcid.org/0000-0002-7707-2331"]},"institutions":[{"id":"https://openalex.org/I1295876152","display_name":"Houston Methodist","ror":"https://ror.org/027zt9171","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1295876152"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]},{"id":"https://openalex.org/I4210147586","display_name":"Texas Children's Hospital","ror":"https://ror.org/05cz92x43","country_code":"US","type":"funder","lineage":["https://openalex.org/I4210147586"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Premal D. Lulla","raw_affiliation_strings":["4Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Houston, TX","institution_ids":["https://openalex.org/I1295876152","https://openalex.org/I181547552","https://openalex.org/I4210147586"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040815890","display_name":"Michael Thomas Byrne","orcid":"https://orcid.org/0000-0002-2966-4877","observed_orcids":["https://orcid.org/0000-0002-2966-4877"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael T. Byrne","raw_affiliation_strings":["5Tennessee Oncology, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Tennessee Oncology, Nashville, TN","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Carol Wong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carol Wong","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075812533","display_name":"Cara Bickers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cara Bickers","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043784646","display_name":"Trever T. Greene","orcid":"https://orcid.org/0000-0003-2960-6631","observed_orcids":["https://orcid.org/0000-0003-2960-6631"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trever Greene","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088108919","display_name":"Lilly  M. Wong","orcid":"https://orcid.org/0000-0001-7460-8658","observed_orcids":["https://orcid.org/0000-0001-7460-8658"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lilly Wong","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112473116","display_name":"Bertha Villa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bertha Villa","raw_affiliation_strings":["7Fate Therapeutics, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Fate Therapeutics, Foster City, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041718874","display_name":"Deepa K. Patel","orcid":"https://orcid.org/0000-0001-8233-3498","observed_orcids":["https://orcid.org/0000-0001-8233-3498"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deepa Patel","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070964738","display_name":"Bahram Bob Valamehr","orcid":"https://orcid.org/0000-0002-5917-3585","observed_orcids":["https://orcid.org/0000-0002-5917-3585"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bahram Bob Valamehr","raw_affiliation_strings":["6Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080126178","display_name":"Rebecca Elstrom","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca Elstrom","raw_affiliation_strings":["8Fate Therapeutics, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Fate Therapeutics, Rome, Italy","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088179815","display_name":"Matthew Alexander Lunning","orcid":"https://orcid.org/0000-0002-2761-7612","observed_orcids":["https://orcid.org/0000-0002-2761-7612"]},"institutions":[{"id":"https://openalex.org/I1307117695","display_name":"Nebraska Medical Center","ror":"https://ror.org/03azxga02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1307117695"]},{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Lunning","raw_affiliation_strings":["9University of Nebraska Medical Center, Omaha, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9University of Nebraska Medical Center, Omaha, NE","institution_ids":["https://openalex.org/I1307117695","https://openalex.org/I59130452"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"144","issue":"Supplement 1","first_page":"6543","last_page":"6543"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipsc-derived-nk-cells","display_name":"iPSC-derived NK cells","score":0.781000018119812},{"id":"https://openalex.org/keywords/car-nk-cell-therapy","display_name":"CAR-NK cell therapy","score":0.7699999809265137},{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.8700000047683716},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.7110000252723694},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-lymphoma","display_name":"relapsed/refractory B-cell lymphoma","score":0.9819999933242798},{"id":"https://openalex.org/keywords/conditioning-chemotherapy","display_name":"conditioning chemotherapy","score":0.4620000123977661},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.7990000247955322},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7269999980926514},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.6263223886489868},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.624508261680603},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.5489271283149719},{"id":"https://openalex.org/C2982819384","wikidata":"https://www.wikidata.org/wiki/Q7078910","display_name":"Off the shelf","level":2,"score":0.5198967456817627},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5149362683296204},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4361913800239563},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40998831391334534},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4042244553565979},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29216301441192627},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27746880054473877},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.23521578311920166},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.2045866847038269},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C117671659","wikidata":"https://www.wikidata.org/wiki/Q11049265","display_name":"Manufacturing engineering","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2024-198684","doi":"https://doi.org/10.1182/blood-2024-198684","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2024-198684","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1619537825","https://openalex.org/W3004611567","https://openalex.org/W3177641494","https://openalex.org/W4283270985","https://openalex.org/W4249018146","https://openalex.org/W4385294737","https://openalex.org/W3090873765","https://openalex.org/W3188370826","https://openalex.org/W4252946123","https://openalex.org/W4307510822"],"abstract_inverted_index":{"Background:":[0],"While":[1],"conditioning":[2,31,220,254,616],"chemotherapy":[3,221,255],"supports":[4],"CAR":[5,100,145,529],"T-cell":[6,574],"expansion":[7],"and":[8,22,41,75,81,105,174,183,225,239,256,297,301,314,339,356,421,440,459,500,558,598,620],"persistence,":[9],"it":[10],"is":[11,46,65,190,609],"associated":[12],"with":[13,162,202,241,252,346,381,454,461,520,550,562,569,590],"significant":[14],"toxicities,":[15],"including":[16,611],"prolonged":[17],"cytopenias,":[18],"poor":[19],"immune":[20,71,88,400],"reconstitution,":[21],"severe":[23],"infections.":[24],"Reducing":[25],"or":[26,233,248,399,428,573],"eliminating":[27],"the":[28,110,121,125,290,320,323,374,450,470,476,594],"need":[29],"for":[30,127,264,269,506],"chemotherapy,":[32],"while":[33,475],"maintaining":[34],"anti-tumor":[35,107,311],"activity,":[36,312],"could":[37],"significantly":[38],"improve":[39],"tolerability":[40,302],"reduce":[42],"non-relapse":[43],"mortality.":[44],"FT522":[45,138,189,213,472,515,582,608],"an":[47,85,117],"iPSC-derived,":[48],"off":[49],"-the-shelf,":[50],"natural":[51],"killer":[52],"(iNK)":[53],"cell":[54,79,158,443,484,531,541],"therapy":[55],"that":[56,155,178],"expresses":[57],"a":[58,144,148,163,194,278,366,466,525,551],"novel":[59,149],"alloimmune":[60],"defense":[61],"receptor":[62,154,169],"(ADR),":[63],"which":[64],"designed":[66],"to":[67,123,136,185,231,288,298,341,351,384,517,524],"target":[68],"activated":[69,113],"host":[70,87],"cells":[72,102,115,549],"expressing":[73],"4-1BB":[74],"uniquely":[76],"enable":[77],"effector":[78,401],"proliferation":[80],"functional":[82],"persistence":[83],"in":[84,109,160,193,199,216,249,328,493,509,588,593,612],"allogeneic":[86],"system":[89],"(Mamonkin":[90],"et":[91,131],"al.,":[92,132],"2020).":[93],"In":[94,134],"nonclinical":[95],"alloreactivity":[96],"models,":[97],"ADR+":[98],"antiCD19":[99],"NK":[101,530],"expand,":[103],"persist,":[104],"maintain":[106],"activity":[108],"presence":[111],"of":[112,212,281,295,303,319,331,368,373,412,449,547,554,556,564,601,607],"T":[114,540,548,603],"from":[116],"unmatched":[118],"donor,":[119],"indicating":[120],"potential":[122,567],"overcome":[124],"requirement":[126],"patient":[128],"lympho-conditioning":[129],"(Williams":[130],"2022).":[133],"addition":[135],"ADR-arming,":[137],"incorporates":[139],"4":[140],"additional":[141],"genetic":[142],"edits:":[143],"targeting":[146],"CD19;":[147],"high-affinity,":[150],"non-cleavable":[151],"CD16":[152],"Fc":[153],"enhances":[156],"antibody-dependent":[157],"cytotoxicity":[159],"combination":[161],"therapeutic":[164],"monoclonal":[165],"antibody":[166],"(mAb);":[167],"IL-15/IL-15":[168],"fusion":[170],"promoting":[171],"cytokine-autonomous":[172],"persistence;":[173],"CD38":[175],"knock":[176],"out":[177],"increases":[179],"mitochondrial":[180],"respiratory":[181],"capacity":[182],"resistance":[184],"oxidative":[186],"stress.":[187],"Methods:":[188],"being":[191],"investigated":[192],"Phase":[195,292],"I":[196],"clinical":[197,274,619],"trial":[198],"patients":[200],"(pts)":[201],"relapsed/refractory":[203],"(R/R)":[204],"B-cell":[205],"lymphomas":[206],"(BCL)":[207],"(ClinicalTrials.gov:":[208],"NCT05950334).":[209],"Three":[210,344],"doses":[211],"are":[214,287],"administered":[215],"Regimen":[217,250,329,494,501,510,613],"A":[218,330],"following":[219],"(fludarabine":[222],"30":[223],"mg/m2":[224,228,236,245,260],"cyclophosphamide":[226],"500":[227],"Days":[229,237],"-5":[230,238],"-3,":[232],"bendamustine":[234],"90":[235],"-4)":[240,247],"rituximab":[242,257],"(R)":[243,258],"375":[244,259],"(Day":[246,261],"B":[251,483,614],"no":[253,382],"-4).":[262],"Observation":[263],"dose":[265,294,325,353],"limiting":[266],"toxicity":[267],"continues":[268],"28":[270],"days.":[271],"Pts":[272,363],"experiencing":[273],"benefit":[275],"may":[276],"receive":[277],"second":[279],"cycle":[280],"their":[282],"assigned":[283],"regimen.":[284,305],"Primary":[285],"objectives":[286,308],"determine":[289],"recommended":[291],"II":[293],"FT522,":[296],"evaluate":[299],"safety":[300],"each":[304],"Additional":[306],"key":[307],"include":[309],"preliminary":[310],"pharmacokinetics,":[313],"anti-product":[315,576],"immunogenicity.":[316],"Results:":[317],"As":[318],"data":[321,622],"cutoff,":[322],"first":[324,385,471,595],"level":[326],"(DL1)":[327],"300":[332],"million":[333,498],"cells/dose":[334],"has":[335,490],"been":[336,491],"fully":[337],"evaluated":[338],"found":[340],"be":[342,624],"tolerable.":[343],"pts":[345,376,452,507,589],"R/R":[347,591],"BCL":[348,592],"were":[349,391,405,415,578],"enrolled":[350],"this":[352],"escalation":[354,606],"cohort":[355,596],"completed":[357],"at":[358],"least":[359],"one":[360,460],"treatment":[361,473],"cycle.":[362],"had":[364,377],"received":[365],"median":[367],"3":[369,375,427,451],"prior":[370,526],"therapies.":[371],"Two":[372,448],"primary":[378],"refractory":[379],"disease,":[380],"response":[383,468],"line":[386],"chemoimmunotherapy.":[387],"No":[388,393,571],"dose-limiting":[389],"toxicities":[390],"reported.":[392],"cytokine":[394],"release":[395],"syndrome,":[396],"graft-versus-host":[397],"disease":[398],"cell-associated":[402],"neurotoxicity":[403],"syndrome":[404],"observed.":[406,579],"Most":[407],"common":[408],"treatment-emergent":[409],"adverse":[410,430],"events":[411,431],"any":[413],"grade":[414],"neutrophil":[416,433],"count":[417,434,438,444],"decreased,":[418,439],"nausea,":[419],"arthralgia":[420],"peripheral":[422,538],"edema":[423],"(N=2":[424],"each).":[425,447],"Grade":[426,455],"higher":[429],"included":[432],"decreased":[435,445],"(N=2),":[436],"lymphocyte":[437],"white":[441],"blood":[442,539],"(N=1":[446],"(one":[453],"3A":[456],"follicular":[457],"lymphoma":[458],"marginal":[462],"zone":[463],"lymphoma)":[464,485],"achieved":[465],"complete":[467,586],"after":[469],"cycle,":[474],"third":[477],"pt":[478],"(triple":[479],"hit":[480],"diffuse":[481],"large":[482],"experienced":[486],"progressive":[487],"disease.":[488],"Enrollment":[489],"initiated":[492],"A,":[495,511],"DL2":[496],"(900":[497],"cells/dose)":[499],"B,":[502],"DL1.":[503],"Pharmacokinetics":[504],"analysis":[505,543],"treated":[508],"DL1":[512],"showed":[513],"detectable":[514],"up":[516],"Day":[518],"15,":[519],"improved":[521],"AUC":[522],"compared":[523],"generation":[527],"CD19-targeted":[528],"product":[532],"candidate":[533],"without":[534,615],"ADR":[535],"arming.":[536],"Preliminary":[537],"subset":[542],"demonstrated":[544,585],"delayed":[545,599],"recovery":[546],"differential":[552],"rate":[553],"reduction":[555],"CD4+":[557],"CD8+":[559],"subsets":[560],"coinciding":[561],"expression":[563],"4-1BB,":[565],"suggesting":[566],"interaction":[568],"ADR.":[570],"B-":[572],"mediated":[575],"responses":[577,587],"Conclusions:":[580],"ADR-armed":[581],"was":[583],"well-tolerated,":[584],"studied,":[597],"emergence":[600],"4-1BB+":[602],"cells.":[604],"Dose":[605],"ongoing,":[610],"chemotherapy.":[617],"Updated":[618],"translational":[621],"will":[623],"presented.":[625]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":6}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}